Literature DB >> 8404957

Hypertension in paediatrics: can pre- and post-captopril technetium-99m dimercaptosuccinic acid renal scans exclude renovascular disease?

I Minty1, M F Lythgoe, I Gordon.   

Abstract

In children over 1 year of age, renal disease is the commonest cause of hypertension. Arteriography is considered the reference method to establish the diagnosis of renovascular disease; however, it is an invasive technique with a high radiation burden for children. This was a retrospective study of pre- and post-capto-technetium-99m dimercaptosuccinic acid (DMSA) imaging compared with arteriography in 18 children between the ages of 3 and 17 years. Alone, the 99mTc-DMSA scan is a sensitive indicator of renal parenchymal disease, although non-specific in suggesting the pathology. The combination of pre- and post-captopril studies may increase the sensitivity and specificity in the diagnosis of renovascular disease in the presence of hypertension. This work suggests that a screening investigation with a low radiation burden can be carried out at most institutions; if the investigation is positive, there will be a high index of suspicion that renovascular disease is the cause of the hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8404957     DOI: 10.1007/bf00181761

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  16 in total

1.  The captopril test: an aid to investigation of hypertension.

Authors:  C E Daman Willems; V Shah; M Uchiyama; M J Dillon
Journal:  Arch Dis Child       Date:  1989-02       Impact factor: 3.791

2.  The role of renal arteriography in pediatric hypertension.

Authors:  A S Clayman; J J Bookstein
Journal:  Radiology       Date:  1973-07       Impact factor: 11.105

3.  Comparison of aortography, renal vein renin sampling, radionuclide scans, ultrasound and the IVU in the investigation of childhood renovascular hypertension.

Authors:  D A Stringer; R de Bruyn; M J Dillon; I Gordon
Journal:  Br J Radiol       Date:  1984-02       Impact factor: 3.039

4.  Reversible diminished renal 99mTc-DMSA uptake during converting-enzyme inhibition in a patient with renal artery stenosis.

Authors:  T K Hovinga; J R Beukhof; W H van Luyk; D A Piers; A J Donker
Journal:  Eur J Nucl Med       Date:  1984

5.  Renovascular hypertension in children and adolescents.

Authors:  P Stanley; M T Gyepes; D L Olson; G F Gates
Journal:  Radiology       Date:  1978-10       Impact factor: 11.105

6.  Single-dose captopril scintigraphy in the diagnosis of renovascular hypertension.

Authors:  G N Sfakianakis; J J Bourgoignie; D Jaffe; G Kyriakides; E Perez-Stable; R C Duncan
Journal:  J Nucl Med       Date:  1987-09       Impact factor: 10.057

Review 7.  Investigation and management of hypertension in children. A personal perspective.

Authors:  M J Dillon
Journal:  Pediatr Nephrol       Date:  1987-01       Impact factor: 3.714

8.  Technetium-99m diethylene triamine penta-acetic acid and dimercaptosuccinic acid in the detection of a segmental branch stenosis of the renal artery by captopril renography.

Authors:  L Bajnok; J Varga; G Kurta
Journal:  Eur J Nucl Med       Date:  1992

9.  Renal vein renin measurements in normotensive children.

Authors:  K G Gerdts; V Shah; J M Savage; M J Dillon
Journal:  J Pediatr       Date:  1979-12       Impact factor: 4.406

10.  Evaluation of hypertensive patients by means of captopril enhanced renal scintigraphy with technetium-99m DTPA.

Authors:  M Dondi; R Franchi; M Levorato; A Zuccalà; R Gaggi; M Mirelli; A Stella; F Marchetta; F Losinno; N Monetti
Journal:  J Nucl Med       Date:  1989-05       Impact factor: 10.057

View more
  9 in total

1.  Hypertension and segmental renal infarction in children: apropos of two cases.

Authors:  Júlia Candel-Pau; Yolanda Castilla-Fernández; Alvaro Madrid-Aris; Ramón Vilalta-Cases; Luis E Lara-Moctezuma; Pilar García-Peña; Mercedes Pérez; José L Nieto-Rey
Journal:  Pediatr Nephrol       Date:  2008-02-21       Impact factor: 3.714

2.  Captopril-enhanced renal scintigraphy in the diagnosis of pediatric hypertension.

Authors:  György Sandor Reusz; Eva Kis; Orsolya Cseprekál; Attila Jozsef Szabó; Eva Kis
Journal:  Pediatr Nephrol       Date:  2009-10-20       Impact factor: 3.714

3.  Pre- and postcaptopril renal scintigraphy as a screening test for renovascular hypertension in children.

Authors:  Sameh Abdulsamea; Peter Anderson; Lorenzo Biassoni; Eileen Brennan; Clare A McLaren; Stephen D Marks; Derek J Roebuck; Sabry Selim; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2009-09-15       Impact factor: 3.714

4.  Update on imaging for suspected renovascular hypertension in children and adolescents.

Authors:  Stephen D Marks; Kjell Tullus
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

5.  Segmental renal artery stenosis diagnosed with captopril renography in a child.

Authors:  William Shing Kee Cheung; Ka Nin Wong; Yiu Chung Wong; Kwok Man Ma
Journal:  Pediatr Radiol       Date:  2004-03-26

Review 6.  Evaluation and management of bilateral renal artery stenosis in children: a case series and review.

Authors:  D Ellis; R Shapiro; V P Scantlebury; R Simmons; R Towbin
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

7.  Captopril scintigraphy in the study of arterial hypertension in pediatrics.

Authors:  Edda Lagomarsino; Pilar Orellana; Jaime Muñoz; Claudia Velásquez; Felipe Cavagnaro; Francisco Valdés
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

Review 8.  Renovascular hypertension in pediatric patients: update on diagnosis and management.

Authors:  Juliana Lacerda de Oliveira Campos; Letícia Bitencourt; Ana Luisa Pedrosa; Diego Ferreira Silva; Filipe Ji Jen Lin; Lucas Teixeira de Oliveira Dias; Ana Cristina Simões E Silva
Journal:  Pediatr Nephrol       Date:  2021-04-13       Impact factor: 3.714

Review 9.  Imaging in the evaluation of renovascular disease.

Authors:  Kjell Tullus; Derek J Roebuck; Clare A McLaren; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2009-10-24       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.